Accueil › Leucémie aiguë myéloïde › Maryland › Baltimore
Essais cliniques pour Leucémie aiguë myéloïde à Baltimore, MD
19 études pour Leucémie aiguë myéloïde recherchent des participants dans et autour de Baltimore (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Recrutement en coursÉtude observationnelleVolontaires sains bienvenus
- Mercy Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- et 2 autres
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Recrutement en coursPhase 1
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Recrutement en coursPhase 2
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Recrutement en coursPhase 1 précoce
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Recrutement en coursPhase 2
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
Recrutement en coursPhase 1/2
- Johns Hopkins University, Baltimore
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Recrutement en coursPhase 3
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Recrutement en coursPhase 2
- John Hopkins School of Medicine, Baltimore
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Recrutement en coursPhase 3
- US-Baltimore MD-UMGCCC, Baltimore
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Recrutement en coursPhase 3
- US-Baltimore MD-UMGCCC, Baltimore
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
Recrutement en coursPhase 1
- University of Maryland/Greenebaum Cancer Center, Baltimore
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Recrutement en coursPhase 1/2
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
Recrutement en coursPhase 1
- Tania Jain, MD, Baltimore
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Recrutement en coursPhase 3
- University of Maryland Medical Center (UMMC), Baltimore
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Recrutement en coursÉtude observationnelle
- Johns Hopkins, Baltimore
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
Recrutement en coursPhase 2
- University of Maryland Greenebaumn Comprehensive Cancer Center, Baltimore
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Recrutement en coursPhase 1/2
- Sibley Memorial Hospital, Baltimore
- University of Maryland, Baltimore
- Johns Hopkins Main Center, Baltimore
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Recrutement en coursPhase 1
- Johns Hopkins School of Medicine, Baltimore
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Recrutement en coursVolontaires sains bienvenus
- Johns Hopkins University, Baltimore
Essais pour Leucémie aiguë myéloïde dans d'autres villes
- Houston, TX85 études
- New York City, NY51 études
- Boston, MA44 études
- Baldwin Park, CA40 études
- Seattle, WA40 études
- Columbus, OH35 études
- Philadelphia, PA34 études
- Durham, NC33 études
- Atlanta, GA30 études
- Tampa, FL29 études
- Chicago, IL26 études
- Portland, OR25 études
Autres études à Baltimore
- Cancer du poumon non à petites cellules60 études
- Cancer du sein47 études
- Cancer de la prostate43 études
- Cancer du poumon40 études
- Cancer (tous types)37 études
- Cancer colorectal31 études
- Cancer du pancréas31 études
- Cancer métastatique28 études
- Obésité25 études
- Insuffisance cardiaque24 études
- Cancer de la vessie24 études
- Accident vasculaire cérébral22 études
Source : ClinicalTrials.gov, données récupérées le 5 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.